Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Herr
    Herr
  2. Vickers
    Vickers
  3. Russo
    Russo
  4. Eastham
    Eastham
  5. Jarnagin
    Jarnagin
  6. Reuter
    Reuter
  7. D'Angelica
    D'Angelica
  8. Kingham
    Kingham
  9. Ladanyi
    Ladanyi
  10. Scher
    Scher

Groups

  1. Surgery (2049)
  2. Department of Medicine (1334)
  3. Urology (1158)
  4. Solid Tumor Oncology Division (829)
  5. Population Sciences Research Program (816)
  6. Survivorship Research (716)
  7. Epidemiology and Biostatistics (685)
  8. Sloan Kettering Institute Faculty (612)
  9. Department of Pathology and Laboratory Medicine (586)
  10. GSK Faculty (582)
Search Within
Formats
  1. Journal Article (3901)
  2. Meeting Abstract (1049)
  3. Editorial (165)
  4. Review (132)
  5. Correspondence (113)
  6. Guidelines (79)
  7. Research Letter (29)
  8. Conference Paper (27)
  9. Book Section (5)
  10. Miscellaneous (3)
Groups
  1. Surgery (2049)
  2. Department of Medicine (1334)
  3. Urology (1158)
  4. Solid Tumor Oncology Division (829)
  5. Population Sciences Research Program (816)
  6. Survivorship Research (716)

More Groups

People
  1. Harry Herr (270)
  2. Andrew Vickers (223)
  3. Paul Russo (185)
  4. Peter Scardino (173)
  5. James Eastham (161)
  6. William Jarnagin (157)

More People

Years
  1. 2025 (96)
  2. 2024 (256)
  3. 2023 (234)
  4. 2022 (264)
  5. 2021 (233)
  6. 2020 (264)

More Years

Publications
  1. Journal of Urology (762)
  2. European Urology (570)
  3. Lancet Oncology (394)
  4. Urology (388)
  5. Journal of the American College of Surgeons (346)
  6. Journal of Molecular Diagnostics (272)

More Publications

Results (5503)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Economic and health-related quality of life burden in endogenous Cushing's syndrome: A systematic literature review
    Meeting Abstract

    Wilson, G. P.; Okeyo, J.; Ortiz, N.; Oak, B.; Zullo, K.; Silber, A.; Moloney, S.; Geer, E. B.
    Value in Health (2022)

    Fulltext@MSK | Save
  • Use of cost per responder models for CAR-T therapies in relapsed or refractory multiple myeloma
    Meeting Abstract

    Martin, T.; Usmani, S. Z.; Joseph, N.; Crivera, C.; Valluri, S.; Jackson, C. C.; Cohen, L.; Singh, S.; Jagannath, S.
    Value in Health (2022)

    Fulltext@MSK | Save
  • A matching-adjusted indirect comparison of asciminib versus ponatinib, nilotinib and dasatinib in chronic phase chronic myeloid leukemia patients after ≥2 tyrosine kinase inhibitors
    Meeting Abstract

    Atallah, E. L.; Maheshwari, V.; Mauro, M. J.; Boquimpani, C.; Rea, D.; Hochhaus, A.; Minami, Y.; Saini, L.; Corbin, R.
    Value in Health (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) from the informCLL registry: A prospective, multicenter, observational study of US patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Cll/Sll)
    Meeting Abstract

    Sharman, J.; Barrientos, J. C.; Ghosh, N.; Brander, D.; Gutierrez, M.; Wu, L.; Panjabi, S.; Upasani, S.; Jermain, M.; Naganuma, M.; more...
    Value in Health (2022)

    Fulltext@MSK | Save
  • Health care resource utilization and costs of car T-cell therapy in patients with diffuse large B-cell lymphoma: A retrospective claims database analysis in the US
    Meeting Abstract

    Davies, K.; Kamalakar, R.; Huang, Y.; Wang, A.; Sail, K.; Doerr, T.; Sharmokh, S.; Mutebi, A.; Salles, G.
    Value in Health (2022)

    Fulltext@MSK | Save
  • Should chemoradiotherapy be standard to maximise cure in localised gastro-oesophageal cancer?
    Editorial

    Reynolds, J. V.; Cowzer, D.; Janjigian, Y. Y.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Combined brachytherapy and ultra-hypofractionated radiotherapy for intermediate-risk prostate cancer: Comparison of toxicity outcomes using a high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy boost
    Journal Article

    Kollmeier, M. A.; Gorovets, D.; Flynn, J.; McBride, S.; Brennan, V.; Beaudry, J.; Cohen, G.; Damato, A.; Zhang, Z.; Zelefsky, M. J.
    Brachytherapy (2022)

    Fulltext@MSK | Save
  • Combination regimens in EGFR-mutated lung cancer: Can we get ORIENT-ed?
    Editorial

    Elkrief, A.; Yu, H.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Inhibiting TGF-β to increase response rates to chemoradiotherapy in rectal cancer
    Editorial

    Romesser, P. B.; Smith, J. J.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Survival impact of variant histology diagnosis in upper tract urothelial carcinoma
    Journal Article

    Nogueira, L. M.; Yip, W.; Assel, M. J.; Tracey, A. T.; Wong, N. C.; Alvim, R. G.; Al-Ahmadie, H.; Bajorin, D. F.; Coleman, J. A.
    Journal of Urology (2022)

    Fulltext@MSK | Save